HER2-targeted antibody-drug conjugate shows 70% response rate in advanced endometrial cancer.

HER2-targeted antibody-drug conjugate shows 70% response rate in advanced endometrial cancer.

Advanced or metastatic endometrial cancer with HER2 expression has limited treatment options. Phase II trial data reported at the Society of Gynecologic Oncology (SGO) meeting showed that an investigational antibody-drug conjugate (ADC)—trastuzumab deruxtecan—achieved response rates of up to 70% in HER2-expressing advanced/metastatic endometrial cancer patients.

This represents a potentially practice-changing finding for a cancer subgroup with historically poor outcomes and few targeted options. ADCs deliver chemotherapy directly to HER2-expressing cancer cells, minimizing systemic toxicity while maximizing tumor exposure.

This data supports further investigation and potential regulatory consideration for this indication.

Key Findings

• Up to 70% of patients responded to investigational ADC in HER2-expressing advanced endometrial cancer
• Phase II data presented at SGO meeting
• HER2 expression is the key biomarker for treatment selection
• ADC approach enables targeted delivery to HER2-expressing endometrial cancer cells
• Advanced/metastatic endometrial cancer has historically limited targeted treatment options

Implications

This response rate is clinically significant for a difficult-to-treat population. HER2 testing should be considered standard of care for advanced endometrial cancer to identify patients who might benefit from ADC therapy. Regulatory submission and approval would represent a major advance.

Caveats

Conference abstract/news report; limited methodological detail; abstract-only from RSS source. Phase II data—larger trials and longer follow-up needed for definitive conclusions. HER2 testing standardization for endometrial cancer is not yet established. ADC toxicity profile needs characterization.

Source: MedPage Hematology/Oncology — 2026-04-12